Poliomyelitis
Conditions
Brief summary
Following a recommendation on October 2017 meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization; low- risk bOPV-using countries may adopt 2 dose fIPV schedule prior to global OPV cessation as it provides better seroconversion than 1 full dose IPV and in the post-cessation era, the 2 fIPV doses will provide sufficient (above 90%) seroconversion. Countries, which delayed the introduction of IPV or had a vaccine stock-out, should provide 1 full dose or 2 fIPV doses to all children who were missed as soon as supply becomes available. The IPV supply situation is expected to improve in 2018; all countries are expected to have access to IPV for their routine immunization programmes from the end of the first quarter of 2018. While immunogenicity after one and two doses of IPV and fIPV has been estimated when administered to younger children ; the immunogenicity of IPV (or fIPV) when administered at 9 months of age or later is not known. We propose to conduct a study to assess the immunogenicity of one and two doses of fIPV and IPV when administered between 9-13 months of age.
Interventions
BIOLOGICALIPV
The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
Sponsors
World Health Organization
International Centre for Diarrhoeal Disease Research, Bangladesh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
• To assess the seroconversion to PV2 after one and two doses of fIPV and IPV when first dose is administered to children aged between 9 and 13 months with second dose administered 2 months later.
Eligibility
Sex/Gender
ALL
Age
9 Months to 13 Months
Healthy volunteers
Yes
Inclusion criteria
1. Apparently healthy children with no obvious clinical symptom of illness 2. Parents/legal guardians of participants willing to give written informed consent and willing to comply with study protocol. 3. Free of obvious health problems (congenital abnormalities, severe malnutrition, acute or chronic diarrhea, bleeding disorder etc) as established by medical history and screening evaluation including clinical examination. 4. Resident of study area.
Exclusion criteria
1. Participation in another clinical trial in the 4 weeks preceding the (first) trial vaccination or planned participation in another clinical trial during the present trial period. 2. A diagnosis or suspicion of congenital or acquired immunodeficiency disorder, malignancy, 3. A diagnosis or suspicion of bleeding disorder 4. Acute or persistent diarrhoea 5. History of allergy or systemic hypersensitivity to any of the vaccine components 6. Chronic illness at a stage that could interfere with trial conduct or completion. 7. Presence of significant malnutrition 8. History of any neurological disorder or history of seizure (febrile or afebrile), or encephalopathy, encephalitis, hypotonic-hyporesponsive episode. 09\. Febrile illness or acute illness on the day of inclusion \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seroconversion to PV2 two months after the first fIPV or IPV dose | 2 months |
Countries
Bangladesh
Contacts
Primary ContactAsma Aziz, MBBS, MPH
Outcome results
None listed